gossypol has been researched along with Prostatic Neoplasms in 37 studies
Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The association of cycle 1 neutropenia with overall survival (OS) was examined post hoc in a randomized phase II trial of 221 men with mCRPC who received docetaxel-prednisone combined with placebo or AT-101 (bcl-2 inhibitor); weekly blood cell counts were performed during the first cycle." | 5.16 | Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. ( Berry, WR; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA, 2012) |
| " The apoptotic effect of gossypol, however, has been demonstrated to be attenuated by the presence of androgen in a prostate cancer xenograft mouse model (Vertebral Cancer of Prostate [VCaP]) treated with AT-101 (R-(-)-gossypol acetic acid)." | 3.76 | AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model. ( Craig, M; McGregor, N; Patel, L; Pienta, KJ; Wang, S; Weidner, S, 2010) |
| "Patients with metastatic prostate cancer scheduled to start, or who had recently (within 6 weeks) initiated, ADT were enrolled." | 2.82 | A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer. ( DiPaola, RS; Goodin, S; Hussain, M; Jeyamohan, C; Kaufman, HL; Liu, G; Mehnert, J; Stadler, WM; Stein, MN; Tereshchenko, IV, 2016) |
| "AT-101 (A), a small molecule oral inhibitor of the Bcl-2 family, has activity alone and in combination with docetaxel (Taxotere) and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC)." | 2.77 | Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. ( Berry, WR; Brookes, M; Burke, JM; Caton, JR; Fleming, MT; Galsky, MD; Holmlund, JT; Hutson, TE; Karlov, P; Leopold, L; Matveev, V; Sonpavde, G; Wood, BA, 2012) |
| "Further investigation of AT-101 in prostate cancer is warranted and trials combining AT-101 with androgen deprivation, as well as with docetaxel chemotherapy are ongoing." | 2.74 | An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. ( Brill, K; Kelly, WK; Leopold, L; Liu, G; Somer, B; Wilding, G, 2009) |
| "Gossypol is a yellow polyphenol isolated from cotton seeds." | 1.51 | Gossypol inhibits 5α-reductase 1 and 3α-hydroxysteroid dehydrogenase: Its possible use for the treatment of prostate cancer. ( Cao, S; Ge, F; Ge, RS; Li, X; Wang, G; Wang, Y; Zhu, Q, 2019) |
| " In this study, the possible synergistic cytotoxic and apoptotic effect of octreotide in combination with AT-101 was investigated in DU-145 hormone and drug refractory prostate cancer cell line." | 1.43 | Octreotide in combination with AT-101 induces cytotoxicity and apoptosis through up-regulation of somatostatin receptors 2 and 5 in DU-145 prostate cancer cells. ( Atmaca, H; Bulut, G; Degirmenci, M; Erdogan, AP; Karabulut, B; Karaca, B; Uslu, R; Uzunoglu, S, 2016) |
| "Prostate cancer is the most common malignancy in males, for which chemotherapy is the usual treatment option in clinical practice." | 1.42 | Inhibitory activity of apogossypol in human prostate cancer in vitro and in vivo. ( An, Q; Hu, X; Huang, X; Yi, J; Zhan, W, 2015) |
| " Notably, the growth of human prostate tumor PC-3 xenografts in mice was significantly suppressed by (-)-gossypol at a dosage of 15 mg/kg/d." | 1.37 | (-)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis. ( Chen, J; Liu, M; Lu, B; Pang, X; Qu, W; Wang, J; Wu, Y; Yi, Z, 2011) |
| "Gossypol reduced the viability of three prostate cancer cell lines (LAPC4, PC3, and DU145) with an IC(50) between 3 and 5 micromol/L." | 1.36 | Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells. ( Farrar, WL; Hurt, EM; Kawasaki, BT; Kim, YS; Milner, JA; Volate, SR; White, J, 2010) |
| "Gossypol has been reported to have a potent anticancer activity in many types of cancer." | 1.36 | Apogossypolone, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces autophagy of PC-3 and LNCaP prostate cancer cells in vitro. ( An, QX; Chen, R; Hu, XB; Huang, XF; Mu, SJ; Wu, DC; Xia, AJ; Yang, SM; Yi, J; Zhan, YH; Zhang, XQ, 2010) |
| "To observe the killing effect of irradiated peripheral blood mononuclear cells (PBMCs) at low dose combined with (-)-gossypol on cultured human prostate cancer LNCaP cells." | 1.36 | [Studies on the killing effect of gamma ray irradiated peripheral blood mononuclear cells combined with (-)-gossypol on human prostate cancer LNCaP cells]. ( Yan, G; Zhan, WH; Zhan, YX; Zhang, XQ, 2010) |
| "Gossypol treatment affects angiogenic cytokine secretion from these two cell lines in a different manner." | 1.35 | Profiling of angiogenic cytokines produced by hormone- and drug-refractory prostate cancer cell lines, PC-3 and DU-145 before and after treatment with gossypol. ( Atmaca, H; Cengiz, E; Erten, C; Gorumlu, G; Gul, MK; Karabulut, B; Karaca, B; Kucukzeybek, Y; Sanli, UA; Uslu, R; Uzunoglu, S, 2008) |
| "Acquisition of metastatic ability by prostatic cancer cells is the most lethal aspect of prostatic cancer progression." | 1.35 | (-)-Gossypol reduces invasiveness in metastatic prostate cancer cells. ( Dowd, MK; Huang, YW; Lin, YC; Wan, PJ; Wang, LS, 2009) |
| " Here, we investigated the efficacy of AT-101 (R-(-)-gossypol acetic acid; a pan small molecule inhibitor of Bcl-2, Bcl-x(L), and Mcl-1) in combination with surgical castration to delay the onset of androgen-independent growth in vivo." | 1.34 | In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. ( Loberg, RD; McGregor, N; Pienta, KJ; Sargent, E; Ying, C, 2007) |
| "The majority of human prostate cancers overexpress the important antiapoptotic proteins Bcl-2 and/or Bcl-xL, which render tumors resistant to radiation therapy." | 1.33 | (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. ( Chen, J; Davis, M; Lawrence, T; Lippman, ME; Liu, M; Rae, JM; Tang, W; Wang, S; Xu, L; Yang, D, 2005) |
| "Gossypol-treated rats exhibited weight reductions in developed MAT-LyLu prostate tumor mass and prostate of 24% (p < 0." | 1.29 | Antiproliferative and antimetastatic effects of gossypol on Dunning prostate cell-bearing Copenhagen rats. ( Brueggemeier, RW; Chang, CJ; Ghosh, PK; Hu, YF; Lin, YC, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.41) | 18.2507 |
| 2000's | 11 (29.73) | 29.6817 |
| 2010's | 23 (62.16) | 24.3611 |
| 2020's | 1 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Aktepe, N | 1 |
| Yukselten, Y | 1 |
| Cao, S | 1 |
| Wang, G | 1 |
| Ge, F | 1 |
| Li, X | 1 |
| Zhu, Q | 1 |
| Ge, RS | 1 |
| Wang, Y | 1 |
| Zhan, W | 1 |
| Hu, X | 1 |
| Yi, J | 2 |
| An, Q | 1 |
| Huang, X | 1 |
| Sarkar, S | 1 |
| Quinn, BA | 2 |
| Shen, XN | 1 |
| Dash, R | 2 |
| Das, SK | 2 |
| Emdad, L | 1 |
| Klibanov, AL | 1 |
| Wang, XY | 2 |
| Pellecchia, M | 3 |
| Sarkar, D | 2 |
| Fisher, PB | 2 |
| Stein, MN | 1 |
| Hussain, M | 1 |
| Stadler, WM | 1 |
| Liu, G | 2 |
| Tereshchenko, IV | 1 |
| Goodin, S | 1 |
| Jeyamohan, C | 1 |
| Kaufman, HL | 1 |
| Mehnert, J | 1 |
| DiPaola, RS | 1 |
| Degirmenci, M | 1 |
| Erdogan, AP | 1 |
| Bulut, G | 1 |
| Atmaca, H | 4 |
| Uzunoglu, S | 4 |
| Karaca, B | 4 |
| Karabulut, B | 4 |
| Uslu, R | 4 |
| Meng, Y | 2 |
| Tang, W | 3 |
| Dai, Y | 1 |
| Wu, X | 2 |
| Liu, M | 3 |
| Ji, Q | 1 |
| Ji, M | 3 |
| Pienta, K | 1 |
| Lawrence, T | 2 |
| Xu, L | 5 |
| Kucukzeybek, Y | 3 |
| Gorumlu, G | 3 |
| Erten, C | 3 |
| Gul, MK | 3 |
| Cengiz, E | 3 |
| Sanli, UA | 3 |
| Kelly, WK | 1 |
| Wilding, G | 1 |
| Leopold, L | 4 |
| Brill, K | 1 |
| Somer, B | 1 |
| Jiang, J | 2 |
| Ye, W | 1 |
| Lin, YC | 4 |
| Huang, YW | 1 |
| Wang, LS | 1 |
| Dowd, MK | 1 |
| Wan, PJ | 1 |
| Zhang, XQ | 3 |
| Huang, XF | 2 |
| Mu, SJ | 2 |
| An, QX | 2 |
| Xia, AJ | 2 |
| Chen, R | 2 |
| Wu, DC | 2 |
| Volate, SR | 1 |
| Kawasaki, BT | 1 |
| Hurt, EM | 1 |
| Milner, JA | 1 |
| Kim, YS | 1 |
| White, J | 1 |
| Farrar, WL | 1 |
| Lian, J | 3 |
| He, F | 2 |
| Karnak, D | 2 |
| Xiang, D | 1 |
| Lawrence, TS | 1 |
| McGregor, N | 2 |
| Patel, L | 1 |
| Craig, M | 1 |
| Weidner, S | 1 |
| Wang, S | 2 |
| Pienta, KJ | 2 |
| Hu, XB | 1 |
| Zhan, YH | 1 |
| Yang, SM | 1 |
| Zhan, WH | 1 |
| Zhan, YX | 1 |
| Yan, G | 1 |
| Pang, X | 1 |
| Wu, Y | 2 |
| Lu, B | 1 |
| Chen, J | 2 |
| Wang, J | 1 |
| Yi, Z | 1 |
| Qu, W | 1 |
| Azab, B | 1 |
| Shen, X | 1 |
| Rahmani, M | 1 |
| Wei, J | 2 |
| Hedvat, M | 1 |
| Dent, P | 1 |
| Dmitriev, IP | 1 |
| Curiel, DT | 1 |
| Grant, S | 1 |
| Wu, B | 1 |
| Stebbins, JL | 1 |
| Reed, JC | 2 |
| Pond, GR | 2 |
| Armstrong, AJ | 1 |
| Wood, BA | 3 |
| Brookes, M | 2 |
| Berry, WR | 3 |
| de Wit, R | 1 |
| Eisenberger, MA | 1 |
| Tannock, IF | 1 |
| Sonpavde, G | 3 |
| Ouyang, DY | 1 |
| Ji, YH | 1 |
| Saltis, M | 1 |
| Xu, LH | 1 |
| Zhang, YT | 1 |
| Zha, QB | 1 |
| Cai, JY | 1 |
| He, XH | 1 |
| Shen, Y | 1 |
| Ye, D | 1 |
| Matveev, V | 1 |
| Burke, JM | 1 |
| Caton, JR | 1 |
| Fleming, MT | 1 |
| Hutson, TE | 1 |
| Galsky, MD | 2 |
| Karlov, P | 1 |
| Holmlund, JT | 1 |
| Slivova, V | 1 |
| Jedinak, A | 1 |
| Sliva, D | 1 |
| Ni, Z | 1 |
| Dai, X | 1 |
| Su, C | 1 |
| Smith, AR | 1 |
| Jackson, RS | 1 |
| Placzek, W | 1 |
| Fernandez, A | 1 |
| Ziaee, S | 1 |
| Chu, CY | 1 |
| Stebbins, J | 1 |
| Kitada, S | 1 |
| Fritz, G | 1 |
| Chung, LW | 1 |
| Bhowmick, NA | 1 |
| Susman, E | 1 |
| Yang, D | 1 |
| Davis, M | 1 |
| Rae, JM | 1 |
| Lippman, ME | 1 |
| Song, JJ | 1 |
| An, JY | 1 |
| Kwon, YT | 1 |
| Lee, YJ | 1 |
| Zhang, M | 1 |
| Liu, H | 1 |
| Tian, Z | 1 |
| Griffith, BN | 1 |
| Li, QQ | 1 |
| Loberg, RD | 1 |
| Ying, C | 1 |
| Sargent, E | 1 |
| Chang, CJ | 1 |
| Ghosh, PK | 1 |
| Hu, YF | 1 |
| Brueggemeier, RW | 2 |
| Shidaifat, F | 1 |
| Canatan, H | 1 |
| Kulp, SK | 1 |
| Sugimoto, Y | 1 |
| Chang, WY | 1 |
| Zhang, Y | 1 |
| Somers, WJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double Blind, Placebo-controlled Multiple-center Phase III Trial of Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression[NCT01977209] | Phase 3 | 204 participants (Anticipated) | Interventional | 2013-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for gossypol and Prostatic Neoplasms
| Article | Year |
|---|---|
A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy | 2016 |
An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Co | 2009 |
Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neopla | 2012 |
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gossypol; Humans; | 2012 |
33 other studies available for gossypol and Prostatic Neoplasms
| Article | Year |
|---|---|
Induction of apoptosis in human hormone-refractory prostate cancer cell lines by using resveratrol in combination with AT-101.
Topics: Apoptosis; Cell Line; Cell Line, Tumor; Gossypol; Hormones; Humans; Male; Prostatic Neoplasms; Resve | 2022 |
Gossypol inhibits 5α-reductase 1 and 3α-hydroxysteroid dehydrogenase: Its possible use for the treatment of prostate cancer.
Topics: 5-alpha Reductase Inhibitors; Alcohol Oxidoreductases; Animals; Gossypol; Hydroxysteroid Dehydrogena | 2019 |
Inhibitory activity of apogossypol in human prostate cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferatio | 2015 |
Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Biological Mimicry; Cell Line, Tumor; Cyste | 2015 |
Octreotide in combination with AT-101 induces cytotoxicity and apoptosis through up-regulation of somatostatin receptors 2 and 5 in DU-145 prostate cancer cells.
Topics: Androgens; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm | 2016 |
Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2 | 2008 |
Profiling of angiogenic cytokines produced by hormone- and drug-refractory prostate cancer cell lines, PC-3 and DU-145 before and after treatment with gossypol.
Topics: Antineoplastic Agents; Caspase 3; Caspase 7; Cell Line, Tumor; Cytokines; Drug Resistance, Neoplasm; | 2008 |
Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination.
Topics: Apoptosis; Cell Line, Tumor; DNA, Complementary; Docetaxel; Dose-Response Relationship, Drug; Drug R | 2010 |
Gossypol inhibits the growth of MAT-LyLu prostate cancer cells by modulation of TGFbeta/Akt signaling.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferatio | 2009 |
(-)-Gossypol reduces invasiveness in metastatic prostate cancer cells.
Topics: Animals; Apoptosis; bcl-X Protein; Blotting, Western; Cell Movement; Cell Proliferation; Contracepti | 2009 |
Targeting apoptosis in the hormone- and drug-resistant prostate cancer cell line, DU-145, by gossypol/zoledronic acid combination.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bone Density Conservation Agents; Cell Line, Tumor; Cell P | 2009 |
Inhibition of proliferation of prostate cancer cell line, PC-3, in vitro and in vivo using (-)-gossypol.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell | 2010 |
Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Contraceptive Agents, Male; Gossypol; Humans; Hyaluronan Recep | 2010 |
A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum.
Topics: Administration, Oral; Androgens; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Pro | 2011 |
AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
Topics: Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Prote | 2010 |
Apogossypolone, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces autophagy of PC-3 and LNCaP prostate cancer cells in vitro.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Drug Screening Assays, Antit | 2010 |
The Bcl-2-Beclin 1 interaction in (-)-gossypol-induced autophagy versus apoptosis in prostate cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Line, Tumor; Gossypol; Humans; M | 2010 |
[Studies on the killing effect of gamma ray irradiated peripheral blood mononuclear cells combined with (-)-gossypol on human prostate cancer LNCaP cells].
Topics: Cell Line, Tumor; Gamma Rays; Gossypol; Humans; Leukocytes, Mononuclear; Male; Prostatic Neoplasms | 2010 |
(-)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis.
Topics: Animals; Aorta; Apoptosis; bcl-X Protein; Cell Differentiation; Cell Line; Cell Movement; Cell Proli | 2011 |
Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Genetic Therap | 2011 |
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Dise | 2012 |
Valproic acid synergistically enhances the cytotoxicity of gossypol in DU145 prostate cancer cells: an iTRTAQ-based quantitative proteomic analysis.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; DNA Damage; Drug Synergism; Energy Metabolism; G | 2011 |
Re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol 2012;61:363-9.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Gossypol; Humans; Male; Prednisone; Prost | 2012 |
Gossypol inhibits growth, invasiveness, and angiogenesis in human prostate cancer cells by modulating NF-κB/AP-1 dependent- and independent-signaling.
Topics: Cell Division; Cell Line, Tumor; Electrophoretic Mobility Shift Assay; G1 Phase; Gossypol; Humans; I | 2012 |
Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation.
Topics: Androgens; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; bcl-2 Homo | 2012 |
Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Transformation, Neoplastic; Disease | 2012 |
Cottonseed-oil byproduct as anticancer radiation sensitiser.
Topics: Animals; Combined Modality Therapy; Cottonseed Oil; Disease Models, Animal; Gossypol; Humans; Male; | 2004 |
(-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer.
Topics: Animals; Apoptosis; bcl-X Protein; Combined Modality Therapy; Gossypol; Humans; Male; Neovasculariza | 2005 |
Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance. Involvement of Bcl-xL.
Topics: Apoptosis; bcl-Associated Death Protein; bcl-X Protein; Cell Line, Tumor; Cell Survival; Gene Expres | 2007 |
Gossypol induces apoptosis in human PC-3 prostate cancer cells by modulating caspase-dependent and caspase-independent cell death pathways.
Topics: Adenocarcinoma; Amino Acid Chloromethyl Ketones; Apoptosis; Apoptosis Inducing Factor; Apoptosis Reg | 2007 |
In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; Combined Modality T | 2007 |
Antiproliferative and antimetastatic effects of gossypol on Dunning prostate cell-bearing Copenhagen rats.
Topics: Androgens; Animals; Antineoplastic Agents; Cell Division; Genitalia, Male; Gossypol; Lung Neoplasms; | 1993 |
Inhibition of human prostate cancer cells growth by gossypol is associated with stimulation of transforming growth factor-beta.
Topics: Cell Cycle; Cell Division; Drug Screening Assays, Antitumor; Gossypol; Humans; Male; Prostatic Neopl | 1996 |